Transcranial direct current stimulation and repetitive transcranial magnetic stimulation in consultation-liaison psychiatry

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 10, 2013, Pages 815-823

  Valiengo, L C L ^a   Bensenor I M ^a   Lotufo, P A ^a   Fraguas, R ^a   Brunoni, A R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Liaison; Major depressive disorder; Neuromodulation; Transcranial stimulation

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; FLUOXETINE; INDINAVIR; MIRTAZAPINE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; PRAMIPEXOLE; PROTEINASE INHIBITOR; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; BIRTH DEFECT; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONSULTATION; DELIRIUM; EPILEPSY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HEADACHE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIAISON PSYCHIATRY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MORTALITY; NEOPLASM; NEUROMODULATION; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PREFRONTAL CORTEX; PREGNANCY; PREVALENCE; PUERPERAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT; TACHYCARDIA; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; URINE RETENTION; WEIGHT GAIN; DEPRESSIVE DISORDER; PATIENT REFERRAL; PROCEDURES; PSYCHIATRY; PSYCHOLOGY;

DEPRESSIVE DISORDER; HUMANS; PSYCHIATRY; REFERRAL AND CONSULTATION; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84886925326     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133115     Document Type: Review

References (87)

1. Christodoulou C, Fineti K, Douzenis A, Moussas G, Michopoulos I, Lykouras L. Transfers to psychiatry through the consultation-liaison psychiatry service: 11 years of experience. Ann Gen Psychiatry 2008; 7: 10, doi: 10.1186/ 1744-859X-7-10.
2. Stern TA. Massachusetts General Hospital handbook of general hospital psychiatry. 6th edn. Philadelphia: Saunders/Elsevier; 2010.
3. Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br J Psychiatry 2011; 198: 179-188, doi: 10.1192/bjp.bp.110.077610.
4. Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 2011; 7: 462-472, doi: 10.1038/nrneurol.2011.104.
5. Jakobsen JC, Hansen JL, Simonsen S, Simonsen E, Gluud C. Effects of cognitive therapy versus interpersonal psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical trials with metaanalyses and trial sequential analyses. Psychol Med 2012; 42: 1343-1357, doi: 10.1017/S0033291711002236.
6. Brunoni AR, Teng CT, Correa C, Imamura M, Brasil-Neto JP, Boechat R, et al. Neuromodulation approaches for the treatment of major depression: challenges and recommendations from a working group meeting. Arq Neuropsiquiatr 2010; 68: 433-451, doi: 10.1590/S0004-282X2010000300021.
7. Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul 2010; 3: 187-199, doi: 10.1016/j.brs.2010.07.003.
8. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009; 39: 65-75, doi: 10.1017/ S0033291708003462.
9. Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebocontrolled trial. Arch Gen Psychiatry 2003; 60: 1002-1008.
10. George MS, Aston-Jones G. Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology 2010; 35: 301-316, doi: 10.1038/npp. 2009.87.
11. Brunoni AR, Ferrucci R, Fregni F, Boggio PS, Priori A. Transcranial direct current stimulation for the treatment of major depressive disorder: a summary of preclinical, clinical and translational findings. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 9-16, doi: 10.1016/j.pnpbp.2012.05.016.
12. Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, et al. Transcranial direct current stimulation: State of the art 2008. Brain Stimul 2008; 1: 206-223, doi: 10.1016/ j.brs.2008.06.004.
13. Kalu UG, Sexton CE, Loo CK, Ebmeier KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med 2012; 42: 1791-1800, doi: 10.1017/S0033291711003059.
14. Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 2013; 70: 383-391, doi: 10.1001/2013.jamapsychiatry.32.
15. Gaspar KC, dos Santos A Jr, de Azevedo RC, Mauro ML, Botega NJ. Depression in general hospital inpatients: challenges for consultation-liaison psychiatry. Rev Bras Psiquiatr 2011; 33: 305-307, doi: 10.1590/S1516-44462011000300016.
16. Levenson JL. The American Psychiatric Publishing Textbook of Psychosomatic Medicine: psychiatric care of the medically ill. 2nd edn. Washington: American Psychiatric Pub.; 2011.
17. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-592, doi: 10.1001/archpsyc.55.7.580.
18. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocardial infarction. Arch Gen Psychiatry 2003; 60: 627-636, doi: 10.1001/archpsyc. 60.6.627.
19. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024-2028, doi: 10.1161/hc4201.097834.
20. Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med 2000; 247: 629-639, doi: 10.1046/ j.1365-2796.2000.00694.x.
21. Freedland KE, Lustman PJ, Carney RM, Hong BA. Underdiagnosis of depression in patients with coronary artery disease: the role of nonspecific symptoms. Int J PsychiatryMed 1992; 22: 221-229, doi: 10.2190/YF10-H39R-NY6M-MT1G.
22. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-709, doi: 10.1001/jama.288.6.701.
23. Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-379, doi: 10.1001/ jama.297.4.367.
24. Manolopoulos VG, Ragia G, Alevizopoulos G. Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. Drug Metabol Drug Interact 2012; 27: 19-31, doi: 10.1515/dmdi-2011-0033.
25. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011; CD006528.
26. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007; 22: 129-133, doi: 10.1002/hup.834.
27. Sakkas P, Psarros C, Papadimitriou GN, Theleritis CG, Soldatos CR. Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 960-962, doi: 10.1016/j.pnpbp.2006.01.023.
28. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161: 1849-1856, doi: 10.1001/archinte.161.15.1849.
29. Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. Am J Cardiol 1999; 84: 348-350, A9, doi: 10.1016/S0002-9149(99)00293-3.
30. Faris R, Purcell H, Henein MY, Coats AJ. Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. Eur J Heart Fail 2002; 4: 541-551, doi: 10.1016/S1388-9842(02)00101-0.
31. Joynt KE, Whellan DJ, O'Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004; 10: 258-271, doi: 10.1016/j.cardfail.2003.09.008.
32. Norra C, Skobel EC, Arndt M, Schauerte P. High impact of depression in heart failure: early diagnosis and treatment options. Int J Cardiol 2008; 125: 220-231, doi: 10.1016/ j.ijcard.2007.05.020.
33. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: 43S-56S, doi: 10.1378/ chest.08-0342.
34. van Manen JG, Bindels PJ, Dekker FW, Ijzermans CJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412-416, doi: 10.1136/thorax.57.5.412.
35. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67, doi: 10.1001/archinte.167.1.60.
36. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 2010; 25: 1209-1221, doi: 10.1002/ gps.2463.
37. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000; 284: 2606-2610, doi: 10.1001/jama.284.20.2606.
38. Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. Chest 2010; 137: 341-347, doi: 10.1378/ chest.09-0614.
39. Laurin C, Moullec G, Bacon SL, Lavoie KL. The impact of psychological distress on exacerbation rates in COPD. Ther Adv Respir Dis 2011; 5: 3-18, doi: 10.1177/1753465810382818.
40. Smith J, Albert P, Bertella E, Lester J, Jack S, Calverley P. Qualitative aspects of breathlessness in health and disease. Thorax 2009; 64: 713-718, doi: 10.1136/thx.2008.104869.
41. Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012; 17: 627-638, doi: 10.1111/j.1440-1843.2012.02148.x.
42. Boyd CA, Benarroch-Gampel J, Sheffield KM, Han Y, Kuo YF, Riall TS. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery 2012; 152: 403-413, doi: 10.1016/j.surg.2012.06.010.
43. Frazzetto P, Vacante M, Malaguarnera M, Vinci E, Catalano F, Cataudella E, et al. Depression in older breast cancer survivors. BMC Surg 2012; 12 (Suppl 1): S14, doi: 10.1186/ 1471-2482-12-S1-S14.
44. Carney CP, Jones L, Woolson RF, Noyes R Jr, Doebbeling BN. Relationship between depression and pancreatic cancer in the general population. Psychosom Med 2003; 65: 884-888, doi: 10.1097/01.PSY.0000088588.23348.D5.
45. Jia L, Jiang SM, Shang YY, Huang YX, Li YJ, Xie DR, et al. Investigation of the incidence of pancreatic cancer-related depression and its relationship with the quality of life of patients. Digestion 2010; 82: 4-9, doi: 10.1159/000253864.
46. Mayr M, Schmid RM. Pancreatic cancer and depression: myth and truth. BMC Cancer 2010; 10: 569, doi: 10.1186/ 1471-2407-10-569.
47. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008; 165: 1251-1255, doi: 10.1176/appi.ajp.2008.08040482.
48. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70: 1688-1697, doi: 10.4088/JCP. 08r04856blu.
49. Kouwenhoven SE, Kirkevold M, Engedal K, Kim HS. Depression in acute stroke: prevalence, dominant symptoms and associated factors. A systematic literature review. Disabil Rehabil 2011; 33: 539-556, doi: 10.3109/09638288. 2010.505997.
50. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157: 351-359, doi: 10.1176/appi.ajp.157. 3.351.
51. Andersen G, Vestergaard K, Riis J, Lauritzen L. Incidence of post-stroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale. Acta Psychiatr Scand 1994; 90: 190-195, doi: 10.1111/j.1600-0447.1994.tb01576.x.
52. Kim BR, Kim DY, Chun MH, Yi JH, Kwon JS. Effect of repetitive transcranial magnetic stimulation on cognition and mood in stroke patients: a double-blind, sham-controlled trial. Am J Phys Med Rehabil 2010; 89: 362-368, doi: 10.1097/PHM.0b013e3181d8a5b1.
53. Jorge RE, Robinson RG, Tateno A, Narushima K, Acion L, Moser D, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004; 55: 398-405, doi: 10.1016/j.biopsych. 2003.08.017.
54. Bueno VF, Brunoni AR, Boggio PS, Bensenor IM, Fregni F. Mood and cognitive effects of transcranial direct current stimulation in post-stroke depression. Neurocase 2011; 17: 318-322, doi: 10.1080/13554794.2010.509319.
55. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy. Significance and phenomenology. Arch Neurol 1986; 43: 766-770, doi: 10.1001/archneur.1986. 00520080014012.
56. Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 2004; 62: 708-713, doi: 10.1212/ 01.WNL.0000113763.11862.26.
57. Barraclough BM. The suicide rate of epilepsy. Acta Psychiatr Scand 1987; 76: 339-345, doi: 10.1111/j.1600-0447.1987.tb05616.x.
58. Currie S, Heathfield KW, Henson RA, Scott DF. Clinical course and prognosis of temporal lobe epilepsy. A survey of 666 patients. Brain 1971; 94: 173-190, doi: 10.1093/brain/ 94.1.173.
59. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289-299.
60. Burn DJ. Beyond the ironmask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17: 445-454, doi: 10.1002/mds.10114.
61. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007; 68: 1230-1236, doi: 10.4088/JCP.v68n0810.
62. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312-315, doi: 10.1034/j.1600-0404.2001.00357.x.
63. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13: 844-851.
64. Epstein CM, Evatt ML, Funk A, Girard-Siqueira L, Lupei N, Slaughter L, et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophysiol 2007; 118: 2189-2194, doi: 10.1016/j.clinph.2007.07.010.
65. Dragasevic N, Potrebic A, Damjanovic A, Stefanova E, Kostic VS. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov Disord 2002; 17: 528-532, doi: 10.1002/mds.10109.
66. Kormos TC. Efficacy of rTMS in the treatment of co-morbid anxiety in depressed patients with Parkinson's disease. Mov Disord 2007; 22: 1836, doi: 10.1002/mds.21613.
67. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1171-1174, doi: 10.1136/ jnnp.2003.027060.
68. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010; 25: 2311-2317, doi: 10.1002/mds.23270.
69. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virusinfected adults in the United States. Arch Gen Psychiatry 2001; 58: 721-728, doi: 10.1001/archpsyc.58.8.721.
70. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007; 21: 374-383, doi: 10.1016/j.bbi.2007.01.010.
71. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002; 159: 1752-1759, doi: 10.1176/appi.ajp.159.10.1752.
72. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev 1997; 145-185.
73. Knotkova H, Rosedale M, Strauss SM, Horne J, Soto E, Cruciani RA, et al. Using Transcranial Direct Current Stimulation to Treat Depression in HIV-Infected Persons: The Outcomes of a Feasibility Study. Front Psychiatry 2012; 3: 59, doi: 10.3389/fpsyt.2012.00059.
74. Campagne DM. The obstetrician and depression during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 116: 125-130, doi: 10.1016/j.ejogrb.2003.11.028.
75. Petersen I, Gilbert R, Evans S, Nazareth I. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2012; 119: 182-183, doi: 10.1097/AOG.0b013e31823f29ee.
76. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569, doi: 10.1136/bmj.b3569.
77. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012; 135: 71-77, doi: 10.1016/ j.pharmthera.2012.03.008.
78. Kim DR, Epperson N, Pare E, Gonzalez JM, Parry S, Thase ME, et al. An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder. J Womens Health 2011; 20: 255-261, doi: 10.1089/jwh.2010.2353.
79. Zhang X, Liu K, Sun J, Zheng Z. Safety and feasibility of repetitive transcranial magnetic stimulation (rTMS) as a treatment for major depression during pregnancy. Arch Womens Ment Health 2010; 13: 369-370, doi: 10.1007/ s00737-010-0163-5.
80. Tan O, Tarhan N, Coban A, Baripoglu SK, Guducu F, Izgi HB, et al. Antidepressant effect of 58 sessions of rTMS in a pregnant woman with recurrent major depressive disorder: A case report. Prim Care Companion J Clin Psychiatry 2008; 10: 69-71, doi: 10.4088/PCC.v10n0113a.
81. Nahas Z, Bohning DE, Molloy MA, Oustz JA, Risch SC, George MS. Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. J Clin Psychiatry 1999; 60: 50-52, doi: 10.4088/JCP.v60n0111.
82. Garcia KS, Flynn P, Pierce KJ, Caudle M. Repetitive transcranial magnetic stimulation treats postpartum depression. Brain Stimul 2010; 3: 36-41, doi: 10.1016/j.brs.2009. 06.001.
83. Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: a safety review. Headache 2010; 50: 1153-1163, doi: 10.1111/ j.1526-4610.2010.01697.x.
84. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009; 120: 2008-2039, doi: 10.1016/j.clinph.2009.08.016.
85. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71: 873-884, doi: 10.4088/JCP.08m04872gre.
86. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapidrate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996; 348: 233-237, doi: 10.1016/S0140-6736(96)01219-6.
87. Zaghi S, Heine N, Fregni F. Brain stimulation for the treatment of pain: A review of costs, clinical effects, and mechanisms of treatment for three different central neuromodulatory approaches. J Pain Manag 2009; 2: 339-352.